Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
AvenCell Therapeutics secures $47M financing from Ligand Pharmaceuticals, including $6M Series C and up to $41M in milestone payments for CAR-T programs.
Amount Raised
$6 Million
Round Type
Series C
San DiegoBiotechnologyHealthcareHealth CarePharmaceuticalBiopharmaInvestors
Description
AvenCell Therapeutics entered a $47 million financing agreement with Ligand Pharmaceuticals to advance its CAR-T therapy programs. The deal includes $6 million in Series C funding and up to $41 million in clinical milestone payments. Ligand will also gain royalty streams on AvenCell's current and future pipeline assets. This financing deepens Ligand's royalty-focused investment model while broadening its partnered asset portfolio.
Fundz sees it the moment Ligand Pharmaceuticals Incorporated raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Ligand Pharmaceuticals Incorporated raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.